Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin

BACKGROUND: Kidney transplant recipients are given induction therapy to rapidly reduce the immune response and prevent rejection. Guidelines recommend that an interleukin-2 receptor antibody (basiliximab) be the first-line agent and that a lymphocyte-depleting agent (antithymocyte globulin [ATG]) be...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Rachel, Quinn, Robert R., Lentine, Krista L., Ravani, Pietro, Ye, Feng, Campbell, Patricia, Wen, Kevin, Broscheit, Chris, Gourishankar, Sita, Lam, Ngan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Clinical Research Quantitative
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573718/
https://www.ncbi.nlm.nih.gov/pubmed/33117549
http://dx.doi.org/10.1177/2054358120964061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573718/
https://www.ncbi.nlm.nih.gov/pubmed/33117549
http://dx.doi.org/10.1177/2054358120964061

Ejemplares similares